ライフサイエンスコーパス: salmonella vaccine

1 ent in L-Sel(-/-) mice immunized with either Salmonella vaccine.

2 strategy for the development of multivalent Salmonella vaccines.

3 sed as a tool for guiding the development of Salmonella vaccines.

4 ield safe efficacious recombinant attenuated Salmonella vaccines.

5 context of the heterologous 987P fimbriae on Salmonella vaccines.

6 uce EAE and orally treated with one of three Salmonella vaccines 6 days postchallenge.

7 re, we constructed and evaluated an improved Salmonella vaccine against M. tuberculosis.

8 Recombinant attenuated Salmonella vaccines against avian coccidiosis were devel

9 These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to eff

10 e development of core glycolipids as a novel Salmonella vaccine candidate.

11 Newly attenuated Salmonella vaccine constructs expressing TGEV S protein

12 ally relevant, live, attenuated, recombinant Salmonella vaccine expressing chicken egg OVA (Salmonell

13 The experimental Salmonella vaccine expressing colonization factor Ag I p

14 Oral immunization of mice with a Salmonella vaccine expressing colonization factor antige

15 Treatment with an anti-inflammatory Salmonella vaccine expressing enterotoxigenic Escherichi

16 mmunization of IL-4-/- mice with recombinant Salmonella vaccine expressing ToxC induced brisk mucosal

17 The development of a subunit Salmonella vaccine has been hindered by the absence of d

18 or the development of recombinant attenuated Salmonella vaccines in humans.

19 igen in hosts immunized with live attenuated Salmonella vaccines is related in part to the amount of

20 The development of safe live, attenuated Salmonella vaccines may be facilitated by detoxification

21 i.n. and possibly even oral delivery of live Salmonella vaccines may be unsafe although it is possibl

22 To assess the potential impact of imperfect Salmonella vaccines on prevalence over time and the erad

23 ed contributor to the protective efficacy of Salmonella vaccines outside the typical studies in C57BL

24 To turn such a recombinant attenuated Salmonella vaccine (RASV) strain into a universal DNA va

25 Live recombinant attenuated Salmonella vaccine (RASV) strains have great potential t

26 The use of recombinant attenuated Salmonella vaccine (RASV) strains is a promising strateg

27 AS) system for use in recombinant attenuated Salmonella vaccine (RASV) strains to enhance immune resp

28 study, we constructed recombinant attenuated Salmonella vaccine (RASV) strains with plasmids expressi

29 e included in various recombinant attenuated Salmonella vaccine (RASV) strains with RDAS derived from

30 al and delivered by a recombinant attenuated Salmonella vaccine (RASV).

31 delivered antigens by recombinant attenuated Salmonella vaccines (RASV) has been the subject of inten

32 nge when delivered by recombinant attenuated Salmonella vaccine (RASVs) strains.

33 Recombinant attenuated Salmonella vaccines (RASVs) have been used extensively t

34 taasdA allele in live recombinant attenuated Salmonella vaccines (RASVs) such as Salmonella enterica

35 The results show that imperfect Salmonella vaccines reduce the prevalence of Salmonella

36 show that a novel OVA-expressing recombinant Salmonella vaccine (Salmonella-OVA) elicits a Th1-biased

37 Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a si

38 effective control measures through applying Salmonella vaccines should be adjusted at different stag

39 ALB/c mice with 10(9) CFU of the recombinant Salmonella vaccine strain carrying pYA3494, immunoglobul

40 Our results indicate that the live Salmonella vaccine strain chi9447 harboring pYA4535 effi

41 The Salmonella vaccine strain expressing an unrelated antige

42 A live oral recombinant Salmonella vaccine strain expressing pneumococcal surfac

43 r location of the recombinant antigen in the Salmonella vaccine strain may contribute to augmenting i

44 Notably, we observed that a newly generated Salmonella vaccine strain not only conferred superior pr

45 The mutations were moved to an attenuated Salmonella vaccine strain to evaluate their effects on i

46 The mice immunized with the auxotrophic Salmonella vaccine strain with the deletion mutation Del

47 ere, following pulmonary immunization with a Salmonella vaccine strain, mouse MAIT cells expanded as

48 on for CA synthesis, was introduced into two Salmonella vaccine strains attenuated by auxotrophic tra

49 Candidate Salmonella vaccine strains synthesizing pneumococcal sur

50 ere constructed and introduced into isogenic Salmonella vaccine strains with or without arabinose-ind

51 In Salmonella vaccine strains with RDAS, the strain with th

52 ure conditions, and for many live attenuated Salmonella vaccine strains, the acid tolerance response

53 icity and efficacy of recombinant attenuated Salmonella vaccine strains.

54 ry useful for expressing foreign antigens in salmonella vaccine strains.

55 vaccine, inclusion of the msbB mutation in a Salmonella vaccine to deliver heterologous antigens has

56 -/-)) mice were orally immunized with either Salmonella vaccine vector or Salmonella vector-expressin

57 sponses to heterologous chimeric fimbriae on Salmonella vaccine vectors can be optimized by using pro

58 These results confirm that oral Salmonella vaccine vectors effectively deliver K99 fimbr

59 studies show that murine dams immunized with Salmonella vaccine vectors stably expressing K99 fimbria

60 ulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors.

61 The safety of dam mutant Salmonella vaccines was evaluated by screening within in

62 Attenuated and dephosphorylated Salmonella vaccines were able to induce adaptive immunit

63 suboptimal protection provided by a subunit Salmonella vaccine which typically induces circulating m

64 t a viable option for developing a live oral Salmonella vaccine, while a wzy mutant that retains one